Sign In
Buy PHIO
$1.03
-0.0050 (-0.485%)
At Close: Jul 31, 2026
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
08:45am, Thursday, 15'th Jan 2026
Registration Link for Phio's Presentation on Thursday, January 22 at 1:45 PM ET King of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clin
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
08:45am, Tuesday, 23'rd Dec 2025
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026 King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
11:30am, Tuesday, 25'th Nov 2025
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its pr
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
08:45am, Monday, 17'th Nov 2025
Presenting INTASYL siRNA Drug Technology King of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical com
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
04:15pm, Thursday, 13'th Nov 2025
Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) in On
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
10:30am, Friday, 07'th Nov 2025
Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprieta
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds
01:40pm, Monday, 03'rd Nov 2025
King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its propr
Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial
07:45am, Monday, 03'rd Nov 2025
Pathologic Clearance: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third Patient Patholo
Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director
10:15am, Friday, 31'st Oct 2025
King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its pro
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
07:45am, Tuesday, 21'st Oct 2025
Registration Link Below for October 28, 2025 12 PM EST Presentation and Live Q&A King of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a cli
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
07:45am, Tuesday, 23'rd Sep 2025
Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&A King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a
Phio Pharmaceuticals to Present at the Life Sciences Future Conference
07:45am, Thursday, 18'th Sep 2025
Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762 King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmace
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
07:45am, Wednesday, 03'rd Sep 2025
Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-762 5th cohort patients now being treated in on-going clinical study King of Prussia, Pennsylvania--(Ne
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
04:15pm, Thursday, 14'th Aug 2025
Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 5th cohort enrolling patients in on-going clinical study King of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Ph
